These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related]
5. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. Issels RD; Bosse D; Abdel-Rahman S; Starck M; Panzer M; Jauch KW; Stiegler H; Berger H; Sauer H; Peter K Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S233-7. PubMed ID: 8453705 [TBL] [Abstract][Full Text] [Related]
6. Clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas treated with a risk-based strategy: A report from Children's Oncology Group study ARST0332. Douglass DP; Coffin CM; Randall RL; Yang Y; Barkauskas DA; Million L; McCarville MB; Pappo AS; Weiss AR; Spunt SL Pediatr Blood Cancer; 2024 Aug; 71(8):e31062. PubMed ID: 38757485 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092 [TBL] [Abstract][Full Text] [Related]
8. Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. Eckert F; Gani C; Kluba T; Mayer F; Kopp HG; Zips D; Bamberg M; Müller AC Strahlenther Onkol; 2013 Jun; 189(6):482-5. PubMed ID: 23604183 [TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821 [TBL] [Abstract][Full Text] [Related]
10. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. Wendtner CM; Abdel-Rahman S; Krych M; Baumert J; Lindner LH; Baur A; Hiddemann W; Issels RD J Clin Oncol; 2002 Jul; 20(14):3156-64. PubMed ID: 12118030 [TBL] [Abstract][Full Text] [Related]
11. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120 [TBL] [Abstract][Full Text] [Related]
12. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. Stubbe F; Agaimy A; Ott O; Lettmaier S; Vassos N; Croner R; Hohenberger W; Fietkau R; Semrau S Cancer Radiother; 2016 Feb; 20(1):6-13. PubMed ID: 26700874 [TBL] [Abstract][Full Text] [Related]
13. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial. Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW; Huber PE; Debus J; Bischof M BMC Cancer; 2014 May; 14():350. PubMed ID: 24885755 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison. Zschaeck S; Wust P; Melcher I; Nadobny J; Rau D; Striefler J; Pahl S; Flörcken A; Kunitz A; Ghadjar P Int J Hyperthermia; 2018; 35(1):1-9. PubMed ID: 30300018 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Issels RD; Abdel-Rahman S; Wendtner C; Falk MH; Kurze V; Sauer H; Aydemir U; Hiddemann W Eur J Cancer; 2001 Sep; 37(13):1599-608. PubMed ID: 11527684 [TBL] [Abstract][Full Text] [Related]
16. [Systemic therapy and hyperthermia for locally advanced soft tissue sarcoma]. Lindner LH; Angele M; Dürr HR; Rauch J; Bruns C Chirurg; 2014 May; 85(5):398-403. PubMed ID: 24740176 [TBL] [Abstract][Full Text] [Related]
17. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. Spunt SL; Francotte N; De Salvo GL; Chi YY; Zanetti I; Hayes-Jordan A; Kao SC; Orbach D; Brennan B; Weiss AR; van Noesel MM; Million L; Alaggio R; Parham DM; Kelsey A; Randall RL; McCarville MB; Bisogno G; Hawkins DS; Ferrari A Eur J Cancer; 2019 May; 112():98-106. PubMed ID: 30954717 [TBL] [Abstract][Full Text] [Related]
18. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Wendtner C; Abdel-Rahman S; Baumert J; Falk MH; Krych M; Santl M; Hiddemann W; Issels RD Eur J Cancer; 2001 Sep; 37(13):1609-16. PubMed ID: 11527685 [TBL] [Abstract][Full Text] [Related]
20. An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Wessalowski R; Schneider DT; Mils O; Hannen M; Calaminus G; Engelbrecht V; Pape H; Willers R; Engert J; Harms D; Göbel U Klin Padiatr; 2003; 215(6):303-9. PubMed ID: 14677093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]